STAMPEDE Trial Treatment & Patient Management.avi

A number of newer treatments have recently become available and have shown initial promise
against prostate cancer. Newer treatments are usually used in prostate cancer when hormone
treatment is no longer effective and the cancer has started to grow again. The aim of this trial,
which is called STAMPEDE, is to assess three of these newer treatments, given earlier in the
course of the disease in combination with hormone treatment.
The three new treatments to be assessed are:
1. Zoledronic acid: Prostate cancer cells can spread to bones and weaken them. Zoledronic
acid is a drug that reduces bone destruction and hardens bones. This may make them more
resistant to attack by cancer cells.
2. Docetaxel: A drug that stops cells replicating that is currently being used to treat lung,
breast and ovarian cancer.
3. Celecoxib: An aspirin-like drug that is used to treat arthritis. It slows down the growth of
cancer cells in the laboratory. We wish to see if it has the same effect on cancer cells in patients.
STAMPEDE will look at the effect of combining one or two of the new treatments described above
with hormone treatment. A computer program will be used to allocate which treatment the
patient receives, using a chance process. Two in every seven patients will receive hormone
treatment only; the other five in seven patients will be split equally between the 5 newer
combined treatment options. The trial will look at the effects of the combined treatments on
quality of life and find out whether the new treatment combinations increase the time when the
cancer is not growing and result in patients living longer. The study will also look at which
treatment provides the greater value for money for the health service. Approximately 3,300
patients will participate in the trial and it will take between 6-10 years to complete.

Category:

Education

Tags:

• STAMPEDE
• Trial
• Treatment
• Patient
• Management
• Prostate
• Cancer
• Clinical
• Medical
• Reasearch
• Council